Development of Improved Dengue 2 Antigen Configurations for a Venezuelan Equine Encephalitis Virus Replicon Particle-Launched Dengue Vaccine

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Last Modified
  • March 21, 2019
Creator
  • Webb, Drue Laine
    • Affiliation: School of Medicine, Department of Microbiology and Immunology
Abstract
  • Dengue has become one of the most important vector-borne diseases. There is currently no licensed dengue vaccine. The envelope glycoprotein is the major target of neutralizing antibodies. Researchers have tried to identify the most antigenic configuration of the envelope protein in different vaccine platforms. In this study, six dengue 2 E configurations, including full-length E, truncated forms of E and the domain III subunit, were expressed as antigen using the Venezuelan equine encephalitis virus replicon paricle system and characterized in vitro and in vivo. Each construct was immunogenic in mice; however, there was a correlation between protein secretion and neutralizing responses. Two truncated and soluble configurations of E encoding amino acid changes from the previously evaluated DEN2 prME-VRP sequence elicited significant neutralizing immune responses. These amino acid changes may be important in the structure of neutralizing epitopes or for proper folding, processing and secretion, leading to improved neutralizing antibody responses.
Date of publication
DOI
Resource type
Rights statement
  • In Copyright
Advisor
  • White, Laura
Language
Access right
  • Open access
Date uploaded
  • October 19, 2010

Relations

Parents:

This work has no parents.

Items

Thumbnail Title Date Uploaded Visibility Actions
file details Development of improved dengue 2 antigen configurations for a Venezuelan equine encephalitis virus replicon particle-launched dengue vaccine 2019-04-12 Public Download